In brief: Living Cell Technologies, Phosphagenics, Rockeby, Antisense, Prima, Proteome Systems

Living Cell Technologies (ASX:LCT) has appointed US based neuroscientist Dr Dwaine F Emerich as chief scientific officer of LCT BioPharma. He has been LCT's US vice-president of research since 2003, joining the company from Sertoli Technologies.

Phosphagenics' (ASX:POH) has appointed Dr Esra Ogru, vice-president of research & development, to the board of directors.

Rockeby biomed (ASX:RBY) has signed a five-year exclusive agreement with Pharmaplan South Africa for the marketing and distribution of CanDia5, its point-of-care test kit to detect Vulvo-Vaginal Candidiasis, in South Africa. The sales of CanDia5 through Pharmaplan are expected to generate revenue for Rockeby in the current financial year.

Antisense Therapeutics' (ASX:ANP) development director Dr Jega Iswaran has resigned. The company's clinical development program will now be overseen by development manager, Nuket Desem.

Prima Biomed (ASX:PRR) has completed inital recruitment of its phase IIa clinical trial in ovarian cancer at the Austin Hospital in Melbourne.

Proteome Systems (ASX:PXL) has signed a heads of agreement with Prince Henry's Institute Medical Research (PHIMR) to combine their IP to develop an ovarian cancer diagnostic test.